Huntsville, AL (PRWEB) June 09, 2011
Microarrays Inc (MI) announces distribution agreements, which will facilitate expansion of MI’s commercial activities into the European Union biotechnology markets. Three distributors, Cambio Ltd (UK and Eire; cambio.com), BioCat GmbH (Germany, Austria, and Switzerland; biocat.com), and Biosolutions Ltd. (Greece, Cyprus, and the Balkans; biosolutions.com) will serve as exclusive distributors for MI products and services, including MI’s custom arrays for biological research, detection and diagnostics markets.
Andrew Jennings, President of Business Development stated, "This is an exciting new chapter in our development, we are thrilled to have such high caliber partners representing us in these markets. I believe their knowledge of the local biotechnology landscape coupled to a commitment to excellence will drive our growth in Europe and provide our customers the highest level of service."
About MI: MI’s corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.
Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010.
In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.